Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (341-350 of 713) with videos related to

Pageof 72
Sort By:
Cancer|September 7, 2006
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|March 8, 2007
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failureHagop Kantarjian, Susan O'Brien, Moshe Talpaz, et al.
Blood|July 2, 2009
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutationsElias Jabbour, Daniel Jones, Hagop M Kantarjian, et al.
Annals of Hematology|May 24, 2017
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratiosGiuseppe Saglio, Philipp le Coutre, Jorge Cortes, et al.
Cancer|September 19, 2008
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 yearsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Leukemia Research|May 15, 2002
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaFarhad Ravandi, Jorge Cortes, Zeev Estrov, et al.
Blood|August 2, 2011
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Blood|August 18, 2011
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignanciesDushyant Verma, Hagop Kantarjian, Sara S Strom, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 17, 2012
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemiaEduardo Cervera, Myrna Candelaria, Omar López-Navarro, et al.
Leukemia Research|November 3, 2009
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapseFarhad Ravandi, Hagop Kantarjian, Stefan Faderl, et al.
Pageof 72

Showing results (341-350 of 713) with videos related to

Sort By:
Pageof 72
Cancer|September 7, 2006
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, et al.
Cancer|March 8, 2007
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failureHagop Kantarjian, Susan O'Brien, Moshe Talpaz, et al.
Blood|July 2, 2009
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutationsElias Jabbour, Daniel Jones, Hagop M Kantarjian, et al.
Annals of Hematology|May 24, 2017
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratiosGiuseppe Saglio, Philipp le Coutre, Jorge Cortes, et al.
Cancer|September 19, 2008
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 yearsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Leukemia Research|May 15, 2002
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemiaFarhad Ravandi, Jorge Cortes, Zeev Estrov, et al.
Blood|August 2, 2011
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Blood|August 18, 2011
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignanciesDushyant Verma, Hagop Kantarjian, Sara S Strom, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 17, 2012
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemiaEduardo Cervera, Myrna Candelaria, Omar López-Navarro, et al.
Leukemia Research|November 3, 2009
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapseFarhad Ravandi, Hagop Kantarjian, Stefan Faderl, et al.
Pageof 72